Sun Pharmaceutical Industries Limited has informed the Exchange about Transcript
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma reported Q1 FY26 consolidated sales of Rs. 1,37,861 crore (up 10.1% YoY) with EBITDA of Rs. 43,017 crore (up 19.2%) and EBITDA margin of 31.1%. Adjusted net profit grew 5.7% to Rs. 29,961 crore, while reported net profit stood at Rs. 22,786 crore after Rs. 8,180 crore in exceptional items (SCD-044 impairment and GXMDL antitrust settlement). India formulations grew 13.9% to Rs. 47,211 crore (8.3% market share, ranked #1), US business grew 1.4% to $473 million, and Global Innovative Medicines rose 16.9% to $311 million. Key highlights include the US launch of Leqselvi for alopecia areata, positive Phase III results for Ilumya in psoriatic arthritis, completed acquisition of Checkpoint Therapeutics (UNLOXCYT), and a strong net cash position of $3.1 billion. Management guided for ~$100 million in direct launch costs for Leqselvi and UNLOXCYT this fiscal year, and a full-year tax rate of around 25%.
Near-term margins may face pressure due to elevated R&D spending (5.6% of sales, ex-exceptional) and ~$100M in launch costs for new innovative products, though the company remains comfortably net cash positive at $3.1 billion. The strong India franchise and growing innovative medicines portfolio (16.9% growth) should support long-term value creation for shareholders.